Part 4: Advanced-Stage and Relapsed/Refractory Hodgkin Lymphoma

Jasleen Randhawa, MD

Fellow, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Sai Ravi Pingali, MD

Fellow, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Timothy S. Fenske, MD

Associate Professor of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Question 2

A 40-year-old man with stage IV-B Hodgkin lymphoma with IPS score of 4 has an excellent performance status without any comorbidities. The patient would like to discuss chemotherapy options and indicates a willingness to accept more intensive treatment if it will increase his chance of cure. With this in mind, which of the following statement(s) is true?

  •   Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide,
    vincristine, procarbazine, prednisone) is associated with improved failure-free
    survival (FFS) and an undisputed overall survival (OS) benefit compared to
    COPP/ABVD (cyclophosphamide, vincristine, procarbazine, prednisone/
    doxorubicin, bleomycin, vinblastine, dacarbazine) or baseline BEACOPP,
    with increased toxicity
  •   Escalated BEACOPP is associated with improved FFS but has not
    consistently shown an improved OS compared to ABVD
  •   Escalated BEACOPP is associated with a higher rate of secondary
    myelodysplasia and acute leukemia compared to less intensive regimens
  •   A and C
  •   A, B, and C

Updated 10/01/2012 • jdw | Copyright ©2014 Turner White Communications